Dean Welsch

TL;DR: This chapter addresses the different metalloprotease enzymes and sub-families and their implication in arthritic diseases, and assess physiological and chemical metalliprotease inhibitors, and for the latter, the current inhibitory classes of compounds being studied.

TL;DR: The first-in-human dose-escalation study of an ERK1/2 inhibitor for the treatment of patients with advanced solid tumors is described, which has an acceptable safety profile with favorable pharmacokinetics and has shown early evidence of clinical activity in NRAS- and BRAF V600- and non-V600-mutant solid-tumor malignancies.

TL;DR: It is demonstrated that the cell-surface protein CD276/B7-H3 is broadly overexpressed by multiple tumor types on both cancer cells and tumor-infiltrating blood vessels, making it a potentially ideal dual-compartment therapeutic target.

TL;DR: Using an integrated multidisciplinary biopsy program, it is demonstrated that real-time genomic characterization of advanced PDAC can identify clinically relevant alterations that inform management of this difficult disease.

TL;DR: It is demonstrated BVD-523 holds promise as a treatment for ERK-dependent cancers, including those whose tumors have acquired resistance to other treatments targeting upstream nodes of the MAPK pathway.